Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 23, Art. 25 (pp. 385-419)    |    2022       

»

Review of drugs for the correction of cns disorders developed as a result of the action of neurotoxicants

A.I. Golovko, E.G. Batotsyrenova, Yu.V. Komov, S.E. Halchitsky, V.A. Kashuro

1 Golikov Research Clinical Center of Toxicology of the Federal Medical Biological Agency, Saint Petersburg, Russia
2 St. Petersburg State Pediatric Medical University, St. Petersburg, Russia
3H.Turner National Medical Research Center for Children's Orthopedics and Trauma Surgery
4The Herzen State Pedagogical University of Russia, Saint Petersburg, Russia
5Research Institute of Hygiene, Occupational Pathology and Human Ecology, Federal State Unitary Enterprise, Federal Medical Biological Agency of Russia

Brief summary

Neuroprotectors are the most important class of drugs, the use of which is necessary in the correction of CNS disorders after severe poisoning by neurotoxicants. The solution of this problem involves the use of rather complex complexes of drugs of various directions. Treatment regimens should also include drugs that are pathogenetic for a particular intoxication. So, in this category of patients, drugs should be used to eliminate insomnia, psychotic, amnestic, neurological and other disorders: hypnotics, mood stabilizers, antipsychotics, etc. It is possible to use drugs that modulate the system of neurotrophic factors in the interests of treating toxic encephalopathies. The direction of research on the synthesis and evaluation of the biological activity of multitarget drugs should also be considered promising.


Key words

neurotoxicity, neuroprotectors, neurodegeneration, neurotrophic factors, multitarget drugs

Reference list

1 Mojokina G. N., Samoilova A. G., Vasileva I. A. Problema neirotoksichnosti lekarstvennih preparatov pri lechenii bolnih tyberkylezom // Tyberkylez i bolezni legkih. - 2020. - T. 98, 10. - S. 58-63.


2 Postnikov S. S., Kostileva M. N., Gracianskaya A. N., Ermilin A. E. i dr. Neirotoksichnost lekarstv // Kachestvennaya klinicheskaya praktika. ‒ 2017. ‒ 4. ‒ S. 68-67.


3 Ahmathanova S.M., Kazakova U.A., Karpov S.M., Shevchenko P.P. Alkagolnaya encefalopatiya: sovremennie metodi lecheniya // Ysp. sovrem. estestvoznaniya. - 2014. - 6. - S. 22-23.


4 Nenasteva A.M., Ysmanova N.N., Pinskaya N.V. Primenenie α-lipoevoi kisloti pri lechenii alkogolnoi polineiropatii // Narkologiya. - 2015. - 12. - S. 18-22.


5 Povarova O.V., Medvedev O.S. Neiroprotektornoe deistvie vitamina K // Eksper. i klinich. farmakol. - 2015. - T. 78, 10. - S. 40-44.


6 Chen Y. Organophosphate-induced brain damage: mechanisms, neuropsychiatric and neurological consequences, and potential therapeutic strategies // Neurotoxicology. - 2012. - Vol. 33, 3. - P. 391-400.


7 Kaur S., Singh S., Chahal K.S., Prakash A. Potential pharmacological strategies for the improved treatment of organophosphate-induced neurotoxicity // Can. J. Physiol. Pharmacol. - 2014. - Vol. 92, 11. - P. 893-911.


8 Li W., Lee M.K. Antiapoptotic property of human α-synuclein in neuronal cell lines is associated with the inhibition of caspase-3 but not caspase-9 activity // J. Neurochem. - 2005. - Vol. 93, 6. - P. 1542-1550.


9 Snigdha S., Smith E.D., Prieto G.A., Cotman C.W. Caspase-3 activation as a bifurcation point between plasticity and cell death // Neurosci. Bull. - 2012. - Vol. 28, 1. - P. 14-24.


10 Hofer M.J., Campbell I.L. Immunoinflammatory diseases of the central nervous system - the tale of two cytokines // Br. J. Pharmacol. - 2016. - Vol. 173, 4. - P. 716-728.


11 Leeds P.R., Yu F., Wang Z., Chiu C.T., Zhang Y., Leng Y., Linares G.R., Chuang D.M. A new avenue for lithium: intervention in traumatic brain injury // ACS Chem. Neurosci. - 2014. - Vol. 5, 6. - P. 422-433.


12 Shabanov P.D. Dokazatelnost neiroprotektornih effektov polipeptidnih preparatov: nereshennie voprosi // Nervnie bolezni. - 2011. - 1(4). - S. 17-20.


13 Voronina T.A., Seredenin S.B. Nootropnie i neiroprotektornie sredstva // Eksper. i klinich. farmakol. - 2007. - T. 70, 4. - S. 44-58.


14 Vasilev S.A. Neirometabolicheskaya terapiya ostrih tyajelih otravlenii: avtoref. dis. d-ra med. nayk / Peterbyrgskii NII skoroi pomoshi imeni I.I. Djanelidze. - SPb., 2008. - 35 s.


15 Afanasev V.V. Citoflavin v intensivnoi terapii: Posobie dlya vrachei. - SPb., 2005. - 36 s.


16 Shabanov P.D. Sykcinatsoderjashie neiroprotektori // Poliklinika. - 2014. - 5-1. - S. 32-34.


17 Livanov G.A., Moroz V.V., Batocirenov B.V., Lodyagin A.N., Andrianov A.U., Bazarova V.G. Pyti farmakologicheskoi korrekcii posledstvii gipoksii pri kriticheskih sostoyaniyah y bolnih s ostrimi otravleniyami // Anesteziol. i reanimatol. - 2003. - 2. - S. 51.


18 Chyhrova M.G., Fedorov A.V., Zaharov V.V. Citoflavin v kompleksnom lechenii bolnih s alkagolnoi zavisimostu // Profilakticheskaya i klinicheskaya medicina. - 2005. - 4. - S. 104-107.


19 Shevchyk M.K., Lichakov A.B., Kolbasov S.E., Savateeva T.N., Lubimov U.A., Melihova M.V., Savateev A.B. Citoflavin v eksperimentalnoi terapii hronicheskoi alkogolnoi intoksikacii // Jyrnal nevrologii i psihiatrii im. C.C. Korsakova. - 2005. - T. 105, 6. - S. 80.


20 Ivnickii U.U., Golovko A.I., Sofronov G.A. Yantarnaya kislota v sisteme sredstv metabolicheskoi korrekcii fynkcionalnogo sostoyaniya i rezistentnosti organizma: Ychebnoe posobie dlya slyshatelei fakylteta rykovodyashego sostava medicinskoi slyjbi. - SPb.: Izd-vo VMedA im. S.M.Kirova, 1998. - 82 s.


21 Traini E., Bramanti V., Amenta F. Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline- containing phospholipid with a still interesting profile as cognition enhancing agent // Curr. Alzheimer Res. - 2013. - Vol. 10, 10. - P. 1070-1079.


22 Vinogradov O.I., Daminov V.D., Ribalko N.V. Primenenie holina alfoscerata (gliatilin) y pacientov s ishemicheskim insyltom // Novosti medicini i farmacii. - 2014. - 518. - S. 17-19.


23 Sergeev D.V. Kognitivnie narysheniya: alternativnie vozmojnosti korrekcii // Nervnie bolezni. - 2015. - ? 3. - S. 24-28.


24 Gareri P., Castagna A., Cotroneo A.M., Putignano S., De Sarro G., Bruni A.C. The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives // Clin. Interv. Aging. - 2015. - Vol. 10. - P. 1421-1429.


25 Roberti G., Tanga L., Michelessi M., Quaranta L., Parisi V., Manni G., Oddone F. Cytidine 5'-diphosphocholine (Citicoline) in glaucoma: rationale of its use, current evidence and future perspectives // Int. J. Mol. Sci. - 2015. - Vol. 16, 12. - P. 28401-28417.


26 Strokov I.A., Fokina A.S., Golovacheva V.A., Fedorova O.S. Alfa-lipoevaya kislota v lechenii diabeticheskoi polineiropatii // Effektivnaya farmakoterapiya. - 2013. - 5. - S. 50-55.


27 Oh J., Kim J.S. Compound K derived from ginseng: neuroprotection and cognitive improvement // Food Funct. - 2016. - Vol. 7, 11. - P. 4506-4515.


28 Beloysova M.A., Tokareva O.G., Gorodeckaya E.A., Kalenikova E.I., Medvedev O.S. Neiroprotektornaya effektivnost vnytrivennogo vvedeniya ybihinona na modeli neobratimoi ishemii golovnogo mozga y kris // Bul. eksper. biol i med. - 2016. - T. 161, 2. - S. 205-207.


29 Lance J., McCabe S., Clancy R.L., Pierce J. Coenzyme Q10 - a therapeutic agent // Medsurg. Nurs. - 2012. - Vol. 21, 6. - P. 367-371.


30 Salama M., Yuan T.F., Machado S., Murillo-Rodríguez E., Vega J.A., Menéndez-González M., Nardi A.E., Arias-Carrión O. Co-enzyme Q10 to treat neurological disorders: basic mechanisms, clinical outcomes, and future research direction // CNS Neurol. Disord. Drug Targets. - 2013. - Vol. 12, 5. - P. 641-664.


31 Shystov E.B., Kashyro V.A., Batocirenova E.G., Zolotoverhaya E.A., Kim A.E., Kostrova T.A. Poliprenoli kak perspektivnie neirofarmakologicheskie sredstva // Biomedicina. - 2020,- T.16, 3, - S. 125-129.


32 Kostrova T.A., Batocirenova E.G., Zolotoverhaya E.A., Kybarskaya L.G., Kashyro V.A., Krasnov K.A. Vliyanie violyrovoi kisloti na antioksidantnyu sistemy v otdalennii period posle otravleniya tiopentalom natriya // Medline.ru. Rossiiskii biomedicinskii jyrnal. - 2021. - T. 22. - S. 551-561.


33 Faden A.I., Wu J., Stoica B.A., Loane D.J. Progressive inflammation-mediated neurodegeneration after traumatic brain or spinal cord injury // Br. J. Pharmacol. - 2016. - Vol. 173, 4. - P. 681-691.


34 Vo T.M., Perry P., Ellerby M., Bohnert K. Is lithium a neuroprotective agent? // Ann. Clin. Psychiatry. - 2015. - Vol. 27, 1. - P. 49-54.


35 Yu F., Wang Z., Tchantchou F., Chiu C.T., Zhang Y., Chuang D.M. Lithium ameliorates neurodegeneration, suppresses neuroinflammation, and improves behavioral performance in a mouse model of traumatic brain injury // J. Neurotrauma. - 2012. - Vol. 29, 2. - P. 362-374.


36 Moosavi F., Hosseini R., Saso L., Firuzi O. Modulation of neurotrophic signaling pathways by polyphenols // Drug Des. Devel. Ther. - 2015. - Vol. 10. - P. 23-42.


37 Solovev V.B., Gengin M.T. Rol neiropeptidov i fermentov ih obmena v adaptacionnih processah i regylyacii metabolizma pri fizicheskoi rabote. - M.: Obshestvo s ogranichennoi otvetstvennostu "Aktyalnost. RF", 2015. - 220 s.


38 Batocirenova E.G., Kashyro V.A., Sharabanov A.V., Kozlov V.K., Kovalenko A.L. Effektivnost peptidnogo prodykta iz gipofiza Severnogo olenya v kachestve antioksidantnogo sredstva pri sochetannom vozdeistvii svetovogo desinhronoza i deprimiryushego toksikanta // Antibiotiki i himioterapiya - 2021. - T. 66, 7-8 . - S. 20-29.


39 Ymnov R.S., Linkova N.S., Havinson V.H. Neiroprotektornie effekti peptidnih bioregylyatorov y ludei raznogo vozrasta: obzor literatyri // Ysp. gerontol. - 2013. - T. 26, 4. - S. 671-678.


40 Agar E. The role of cannabinoids and leptin in neurological diseases // Acta Neurol. Scand. - 2015. - Vol. 132, 6. - P. 371-380.


41 Nekoui A., Del Carmen Escalante Tresierra V., Abdolmohammadi S., Shedid D., Blaise G. Neuroprotective effect of erythropoietin in postoperation cervical spinal cord injury: case report and review // Anesth. Pain Med. - 2015. - Vol. 5, 6. - Article e28849. - 4 p.


42 Kozlovskii I.I., Andreeva L.A., Kozlovskaya M.M., Nadorova A.V., Kolik L.G. O roli opioidnoi sistemi v formirovanii osobennostei anksioliticheskogo deistviya peptidnogo preparata selanka // Eksper. i klinich. farmakol. - 2012. - T. 75, 2. - S. 10-13.


43 Gysev E.I., Skvorcova V.I. Neiroprotektivnaya terapiya ishemicheskogo insylta. I. Pervichnaya neiroprotekciya // Jyrnal nevrologii i psihiatrii im. S.S. Korsakova. - 2002. - T. 102, 5. - Priloj. - S. 3-16.


44 Bodienkova G.M., Boklajenko E.V. Rol neirotroficheskogo faktora golovnogo mozga v mehanizmah razvitiya neirointoksikacii rtytu // Ysp. sovrem. estestvoznaniya. - 2015. - 5. - S. 105-108.


45 Batocirenova E.G., Kashyro V.A., Sharabanov A.V. Farmakologicheskaya korrekciya otdalennih posledstvii ostrogo tyajelogo otravleniya tiopentalom natriya v ysloviyah hronicheskogo svetovogo desinhronoza // Biomedicina. - 2021. - T. 17, 3. - S. 23-28.


46 Belluardo N., Mudò G., Blum M., Fuxe K. Central nicotinic receptors, neurotrophic factors and neuroprotection // Behav. Brain Res. - 2000. - Vol. 113, 1-2. - P. 21-34.


47 Carvalho I.M., Coelho P.B., Costa P.C., Marques C.S., Oliveira R.S., Ferreira D.C. Current neurogenic and neuroprotective strategies to prevent and treat neurodegenerative and neuropsychiatric disorders // Neuromolecular Med. - 2015. - Vol. 17, 4. - P. 404-422.


48 Lyashenko A.A., Yvarov V.U. K voprosy o sistematizacii citokinov // Ysp. sovrem. biol. - 2001. - T. 121, 6. - S. 589-603.


49 Stepanichev M.U. Citokini kak neiromodylyatori v centralnoi nervnoi sisteme // Neirohimiya. - 2005. - T. 22, 1. - S. 5-11.


50 Niwa M., Nitta A., Yamada K., Nabeshima T. The roles of glial cell line-derived neurotrophic factor, tumor necrosis factor-α, and an inducer of these factors in drug dependence // J. Pharmacol. Sci. - 2007. - Vol. 104, 2. - P. 116-121.


51 Neiropeptidi i rostovie faktori mozga. Informacionno-spravochnoe izdanie / Sostavitel O.A.Gomazkov. - M., 2002. - 239 s.


52 Messer C.J., Eisch A.J., Carlezon W.A. Jr., Whisler K., Shen L., Wolf D.H., Westphal H., Collins F., Russell D.S., Nestler E.J. Role for GDNF in biochemical and behavioral adaptations to drugs of abuse // Neuron. - 2000. - Vol. 26, 1. - P. 247-257.


53 Sariola H., Saarma M. Novel functions and signalling pathways for GDNF // J. Cell Sci. - 2003. - Vol. 116. - Pt. 19. - P. 3855-3862.


54 Lindholm P., Saarma M. Novel CDNF/MANF family of neurotrophic factors // Dev. Neurobiol. - 2010. - Vol. 70, 5. - P. 360-371.


55 Gomazkov O.A. Starenie mozga i neirotrofini. Kletochnie i molekylyarnie principi neirotroficheskoi terapii. - M.: Izd-vo IKAR, 2011. - 92 s. URL: http://www.ibmc.msk.ru/content/monography/GomazkovOA3.pdf


56 Holtzman D.M., Mobley W.C. Neurotrophic factors and neurologic disease // West J. Med. - 1994. - Vol. 161, 3. - P. 246-254.


57 Tyler W.J., Alonso M., Bramham C.R., Pozzo-Miller L.D. From acquisition to consolidation: on the role of brain-derived neurotrophic factor signaling in hippocampal-dependent learning // Learn. Mem. - 2002. - Vol. 9, 5. - P. 224-237.


58 Rydnickaya E.A., Kolosova N.G., Stefanova N.A. Neirotroficheskoe obespechenie golovnogo mozga v ontogeneze i pri razvitii neirodegenerativnih zabolevanii // Vestn. Mosk. Yn-ta. Ser. 16. Biologiya. - 2016. - 4. - S. 72-82.


59 Sohrabji F., Lewis D.K. Estrogen-BDNF interactions: implications for neurodegenerative diseases // Front. Neuroendocrinol. - 2006. - Vol. 27, 4. - P. 404-414.


60 Vedynova M.V., Saharnova T.A., Mitroshina E.V., Myhina I.V. Antigipoksicheskie svoistva neirotroficheskogo faktora golovnogo mozga pri modelirovanii gipoksii v dissociirovannih kyltyrah gippokampa // Sovrem. tehnol. v med. - 2012. - 4. - S. 17-23.


61 Spina M.B., Squinto S.P., Miller J., Lindsay R.M., Hyman C. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system // J. Neurochem. - 1992. - Vol. 59, 1. - P. 99-106.


62 Almeida R.D., Manadas B.J., Melo C.V., Gomes J.R., Mendes C.S., Grãos M.M., Carvalho R.F., Carvalho A.P., Duarte C.B. Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways // Cell Death Differ. - 2005. - Vol. 12, 10. - P. 1329-1343.


63 Leal G., Comprido D., Duarte C.B. BDNF-induced local protein synthesis and synaptic plasticity // Neuropharmacology. - 2014. - Vol. 76. - Pt. C. - P. 639-656.


64 Pollack S.J., Harper S.J. Small molecule Trk receptor agonists and other neurotrophic factor mimetics // Curr. Drug Targets CNS Neurol. Disord. - 2002. - Vol. 1, 1. - P. 59-80.


65 Sofroniew M.V., Howe C.L., Mobley W.C. Nerve growth factor signaling, neuroprotection, and neural repair // Annu. Rev. Neurosci. - 2001. - Vol. 24. - P. 1217-1281.


66 Steiner J.P., Nath A. Neurotrophin strategies for neuroprotection: are they sufficient? // J. Neuroimmune Pharmacol. - 2014. - Vol. 9, 2. - P. 182-194.


67 Grivennikov I.A. Molekylyarno-geneticheskie podhodi k peptidnoi farmakoterapii neirodegenerativnih zabolevanii: avtoref. dis. doktora biol. nayk / Naych.-issled. in-t farmakologii RAMN. - M., 2008. - 42 s.


68 Hudson S.A., Tabet N. Acetyl-L-carnitine for dementia // Cochrane Database Syst. Rev. - 2003. - 2. - Article CD003158.


69 Genrihs E.E., Bobrov M.U., Andrianova E.L., Greckaya N.M., Lijin A.A., Blajenova A.V., Frymkina L.E., Bezyglov V.V., Haspekov L.G. Modylyatori endogennoi kannabinoidnoi sistemi kak neiroprotektori // Annali klinich. i eksper. nevrol. - 2010. - T. 4, 4. - S. 37-42.


70 Sarne Y., Asaf F., Fishbein M., Gafni M., Keren O. The dual neuroprotective-neurotoxic profile of cannabinoid drugs // Br. J. Pharmacol. - 2011. - Vol. 163, 7. - P. 1391-1401.


71 Zhang M., Martin B.R., Adler M.W., Razdan R.J., Kong W., Ganea D., Tuma R.F. Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke // J. Neuroimmune Pharmacol. - 2009. - Vol. 4, 2. - P. 249-259sufficient? // J. Neuroimmune Pharmacol. - 2014. - Vol. 9, 2. - P. 182-194.


72 Calabrese V., Mancuso C., Calvani M., Rizzarelli E., Butterfield D.A., Stella A.M. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity // Nat. Rev. Neurosci. - 2007. - Vol. 8, 10. - P. 766-775.


73 Bespalov A.U., Zvartay E.E. Neiropsihofarmakologiya antagonistov NMDA-receptorov. - SPb.: Nevskii dialekt. - 2000. - 297 s.


74 Ohotin V.E., Kalinichenko S.G., Dydina U.V. NO-ergicheskaya transmissiya i NO kak obemnii neiroperedatchik. Vliyanie NO na mehanizmi sinapticheskoi plastichnosti i epileptogenez // Ysp. fiziol. nayk. - 2002. - T. 33, 2. - S. 41-55.


75 Kolesnikov Y.A., Pan Y.X., Babey A.M., Jain S., Wilson R., Pasternak G.W. Functionally differentiating two neuronal nitric oxide synthase isoforms through antisense mapping: evidence for opposing NO actions on morphine analgesia and tolerance // Proc. Natl. Acad. Sci. U S A. - 1997. - Vol. 94, 15. - P. 8220-8225.


76 Menshikova E.B., Zenkov N.K., Reytov V.P. Oksid azota i NO-sintazi v organizme mlekopitaushih pri razlichnih fynkcionalnih sostoyaniyah // Biohimiya. - 2000. - T. 65, 4. - S. 485-503.


77 Seraya I.P., Narcissov Ya.R. Sovremennie predstavleniya o biologicheskoi roli oksida azota // Ysp. sovrem. biol. - 2002. - T. 122, 3. - S. 249-258.


78 Cao J.L., Zeng Y.M., Zhang L.C., Gu J., Liu H.F., Zhou W.H., Yang G.D. NO mediated increase of Fos protein and NMDA1A R mRNA expression in rat spinal cord during morphine withdrawal // Acta Pharmacol. Sin. - 2001. - Vol. 22, 6. - P. 505-511.


79 Li J., Li X., Pei G., Qin B.Y. Correlation between inhibitions of morphine withdrawal and nitric-oxide synthase by agmatine // Zhongguo Yao Li Xue Bao. - 1999. - Vol. 20, 4. - P. 375-380.


80 Medvedev I.O., Dravolina O.A., Bespalov A.Y. Differential effects of nitric oxide synthase inhibitor, 7-nitroindazole, on discriminative stimulus and somatic effects of naloxone in morphine-dependent rats // Eur. J. Pharmacol. - 1999. - Vol. 377, 2-3. - P. 183-186.


81 Ozek M., Uresin Y., Gungor M. Comparison of the effects of specific and nonspecific inhibition of nitric oxide synthase on morphine analgesia, tolerance and dependence in mice // Life Sci. - 2003. - Vol. 72, 17. - P. 1943-1951.


82 Pineda J., Torrecilla M., Martin-Ruiz R., Ugedo L. Attenuation of withdrawal-induced hyperactivity of locus coeruleus neurones by inhibitors of nitric oxide synthase in morphine-dependent rats // Neuropharmacology. - 1998. - Vol. 37, ? 6. - P. 759-767.


83 Homayoun H., Khavandgar S., Namiranian K., Dehpour A.R. The effect of cyclosporin A on morphine tolerance and dependence: involvement of L-arginine/nitric oxide pathway // Eur. J. Pharmacol. - 2002. - Vol. 452, 1. - P. 67-75.


84 Balez R., Ooi L. Getting to NO Alzheimer's disease: Neuroprotection versus neurotoxicity mediated by nitric oxide // Oxid. Med. Cell. Longev. - 2016. - Vol. 2016. - Article ID 3806157. - 8 p.


85 Boje K.M. Nitric oxide neurotoxicity in neurodegenerative diseases // Front. Biosci. - 2004. - Vol. 9. - P. 763-776.


86 Birks J.S., Grimley Evans J. Rivastigmine for Alzheimer's disease // Cochrane Database Syst. Rev. - 2015. - 4. - Article CD001191. - 82 p.


87 Campos C., Rocha N.B., Vieira R.T., Rocha S.A., Telles-Correia D., Paes F., Yuan T., Nardi A.E., Arias-Carrión O., Machado S., Caixeta L. Treatment of cognitive deficits in Alzheimer's disease: A psychopharmacological review // Psychiatr. Danub. - 2016. - Vol. 28, 1. - P. 2-12.


88 Laver K., Dyer S., Whitehead C., Clemson L., Crotty M. Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews // BMJ Open. - 2016. - Vol. 6, 4. - Article e010767. - 13 p.


89 Matsunaga S., Kishi T., Yasue I., Iwata N. Cholinesterase inhibitors for Lewy Body disorders: A meta-analysis // Int. J. Neuropsychopharmacol. - 2015. - Vol. 19, 2. - Article pyv086. - 15 p.


90 Prati F., Cavalli A., Bolognesi M.L. Navigating the chemical space of multitarget-directed ligands: from hybrids to fragments in Alzheimer's disease // Molecules. - 2016. - Vol. 21, 4. - Article 466. - 12 p.


91 Cavalli A., Bolognesi M.L., Minarini A., Rosini M., Tumiatti V., Recanatini M., Melchiorre C. Multi-target-directed ligands to combat neurodegenerative diseases // J. Med. Chem. - 2008. - Vol. 51, 3. - P. 347-372.


92 Morphy R., Rankovic Z. The physicochemical challenges of designing multiple ligands // J. Med. Chem. - 2006. - Vol. 49, 16. - P. 4961-4970.


93 Lecoutey C., Hedou D., Freret T., Giannoni P., Gaven F., Since M., Bouet V., Ballandonne C., Corvaisier S., Malzert Fréon A., Mignani S., Cresteil T., Boulouard M., Claeysen S., Rochais C., Dallemagne P. Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment // Proc. Natl. Acad. Sci. U S A. - 2014. - Vol. 111, 36. - P. E3825-E3830.


94 Wang Z., Wang Y., Wang B., Li W., Huang L., Li X. Design, synthesis, and evaluation of orally available clioquinol-voracin M hybrids as multitarget-directed ligands for cognitive improvement in a rat model of neurodegeneration in Alzheimer's disease // J. Med. Chem. - 2015. - Vol. 58, 21. - P. 8616-8637.


95 Fang J., Li Y., Liu R., Pang X., Li C., Yang R., He Y., Lian W., Liu A.L., Du G.H. Discovery of multitarget-directed ligands against Alzheimer's disease through systematic prediction of chemical-protein interactions // J. Chem. Inf. Model. - 2015. - Vol. 55, 1. - P. 149-164.


96 Li Y., Peng P., Tang L., Hu Y., Hu Y., Sheng R. Design, synthesis and evaluation of rivastigmine and curcumin hybrids as site-activated multitarget-directed ligands for Alzheimer's disease therapy // Bioorg. Med. Chem. - 2014. - Vol. 22, 17. - P. 4717-4725.


97 Huang W., Tang L., Shi Y., Huang S., Xu L., Sheng R., Wu P., Li J., Zhou N., Hu Y. Searching for the multi-target-directed ligands against Alzheimer's disease: discovery of quinoxaline-based hybrid compounds with AChE, H₃R and BACE 1 inhibitory activities // Bioorg. Med. Chem. - 2011. - Vol. 19, 23. - P. 7158-7167.


98 Huang L., Lu C., Sun Y., Mao F., Luo Z., Su T., Jiang H., Shan W., Li X. Multitarget-directed benzylideneindanone derivatives: anti-β-amyloid (Aβ) aggregation, antioxidant/t, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer's disease // J. Med. Chem. - 2012. - Vol. 55, 19. - P. 8483-8492.


99 Wang L., Esteban G., Ojima M., Bautista-Aguilera O.M., Inokuchi T., Moraleda I., Iriepa I., Samadi A., Youdim M.B., Romero A., Soriano E., Herrero R., Fernández Fernández A.P., Ricardo-Martínez-Murillo, Marco-Contelles J., Unzeta M. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease // Eur. J. Med. Chem. - 2014. - Vol. 80. - P. 543-561.


100 Vila M., Przedborski S. Targeting programmed cell death in neurodegenerative diseases // Nat. Rev. Neurosci. - 2003. - Vol. 4, 5. - P. 365-375.


101 Kudelova J., Fleischmannova J., Adamova E., Matalova E. Pharmacological caspase inhibitors: research towards therapeutic perspectives // J. Physiol. Pharmacol. - 2015. - Vol. 66, 4. - P. 473-482.


102 Poreba M., Szalek A., Kasperkiewicz P., Rut W., Salvesen G.S., Drag M. Small molecule active site directed tools for studying human caspases // Chem. Rev. - 2015. - Vol. 115, 22. - P. 12546-12629.


103 Troy C.M., Jean Y.Y. Caspases: therapeutic targets in neurologic disease // Neurotherapeutics. - 2015. - Vol. 12, 1. - P. 42-48.


104 Toulmond S., Tang K., Bureau Y., Ashdown H., Degen S., O'Donnell R., Tam J., Han Y., Colucci J., Giroux A., Zhu Y., Boucher M., Pikounis B., Xanthoudakis S., Roy S., Rigby M., Zamboni R., Robertson G.S., Ng G.Y., Nicholson D.W., Flückiger J.P. Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease // Br. J. Pharmacol. - 2004. - Vol. 141, 4. - P. 689-697.


105 Han B.H., Xu D., Choi J., Han Y., Xanthoudakis S., Roy S., Tam J., Vaillancourt J., Colucci J., Siman R., Giroux A., Robertson G.S., Zamboni R., Nicholson D.W., Holtzman D.M. Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxic-ischemic brain injury // J. Biol. Chem. - 2002. - Vol. 277, 33. - P. 30128-30136.


106 Yang L., Sugama S., Mischak R.P., Kiaei M., Bizat N., Brouillet E., Joh T.H., Beal M.F. A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo // Neurobiol. Dis. - 2004. - Vol. 17, 2. - P. 250-259.


107 Alesenko A.V., Bachyrin S.O., Gyryanova S.V., Karatasso U.O., Shevcova E.F., Shingarova L.N. Faktor nekroza opyholei-alfa - potencialnaya mishen dlya neiroprotektora dimebona // Biomed. himiya. - 2016. - T. 62, 4. - S. 418-425.


108 Sweetlove M. Phase III CONCEPT trial of latrepirdine. Negative results // Pharm. Med. - 2012. - Vol. 26, 2. - P. 113-115.


109 Zindo F.T., Joubert J., Malan S.F. Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond // Future Med. Chem. - 2015. - Vol. 7, 5. - P. 609-629.